^
Association details:
| Biomarker: | FGFR2 V564L |
|---|---|
| Cancer: | Cholangiocarcinoma |
| Drug: | tinengotinib (TT-00420) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
95MO - Tinengotinib in patients with advanced, fibroblast growth factor receptor (FGFR) inhibitor refractory/relapsed cholangiocarcinoma
Published date:
10/16/2023
Excerpt:
10 pts who developed FGFR2 kinase domain mutations (N549D/H/K/T, V564F/I/L, E565A/G/K) detected by liquid biopsy at baseline had ORR of 50%, DCR of 90% and mPFS of 7.03 months (95%CI, 0.95-11.86)...These pooled results suggest that tinengotinib has a manageable toxicity profile in CCA pts. Notable clinical benefit was noted with tinengotinib in FGFR-altered CCA pts with acquired resistance to prior FGFRi.
Trial ID:
